Intellectual Property India Publishes Patent Application for 'Claudin 18.2 Targeting Chimeric Antigen Receptors And Binding Agents And Uses Thereof' Filed by Allogene Therapeutics, Inc.; and Pfizer Inc.

MUMBAI, India, June 27 -- Intellectual Property India has published a patent application (202517055611 A) filed by Allogene Therapeutics, Inc.; and Pfizer Inc., San Francisco, on June 9, for 'claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof.'

Inventor(s) include Li, Zhe; Panowski, Siler; Sasu, Barbra Johnson; Smith, Bryan A.; Van Blarcom, Thomas John; Sai, Tao; and Zhu, Guoyun.

The application for the patent was published on June 27, under issue no. 26/2025.

According to the abstract released by the Intellectual Property India: "Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs."

The patent application was internationally filed on Nov. 28, 2023, under International application No.PCT/US2023/081330.

Disclaimer: Curated by HT Syndication.